416 related articles for article (PubMed ID: 22865271)
41. [Nephrogenic systemic fibrosis and gadolinium contrast agents].
Aguilera C; Agustí A
Med Clin (Barc); 2011 May; 136(14):643-5. PubMed ID: 21397280
[No Abstract] [Full Text] [Related]
42. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update.
Idée JM; Port M; Dencausse A; Lancelot E; Corot C
Radiol Clin North Am; 2009 Sep; 47(5):855-69, vii. PubMed ID: 19744600
[TBL] [Abstract][Full Text] [Related]
43. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents.
Kitajima K; Maeda T; Watanabe S; Ueno Y; Sugimura K
Int J Urol; 2012 Sep; 19(9):806-11. PubMed ID: 22571387
[TBL] [Abstract][Full Text] [Related]
44. Gadolinium in pediatric cardiovascular magnetic resonance: what we know and how we practice.
Meng H; Grosse-Wortmann L
J Cardiovasc Magn Reson; 2012 Aug; 14(1):56. PubMed ID: 22871150
[TBL] [Abstract][Full Text] [Related]
45. Nephrogenic systemic fibrosis: clinical spectrum of disease.
Mayr M; Burkhalter F; Bongartz G
J Magn Reson Imaging; 2009 Dec; 30(6):1289-97. PubMed ID: 19937929
[TBL] [Abstract][Full Text] [Related]
46. Nephrogenic systemic fibrosis: a review of the new conundrum.
Goenka AH; Das CJ; Sharma R
Natl Med J India; 2009; 22(6):302-6. PubMed ID: 20384019
[TBL] [Abstract][Full Text] [Related]
47. Gadolinium and nephrogenic systemic fibrosis.
Runge VM
AJR Am J Roentgenol; 2009 Apr; 192(4):W195-6; discussion W197. PubMed ID: 19304681
[No Abstract] [Full Text] [Related]
48. Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis.
Piera-Velazquez S; Louneva N; Fertala J; Wermuth PJ; Del Galdo F; Jimenez SA
Ann Rheum Dis; 2010 Nov; 69(11):2017-23. PubMed ID: 20570839
[TBL] [Abstract][Full Text] [Related]
49. Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update.
Ramalho J; Semelka RC; Ramalho M; Nunes RH; AlObaidy M; Castillo M
AJNR Am J Neuroradiol; 2016 Jul; 37(7):1192-8. PubMed ID: 26659341
[TBL] [Abstract][Full Text] [Related]
50. Correction to the relative risk calculation for gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis.
Jain R; Levine M
Radiology; 2010 Apr; 255(1):307-8; author reply 308. PubMed ID: 20308469
[No Abstract] [Full Text] [Related]
51. [Gadolinium and nephrogenic systemic fibrosis. All quiet? Yes...! No...! Maybe...!].
Balducci A; Tamburrini O
G Ital Nefrol; 2011; 28(1):4-6. PubMed ID: 21341233
[No Abstract] [Full Text] [Related]
52. [Nephrogenic systemic fibrosis: a severe complication of use to gadolinium in patients with kidney failure].
Mundim JS; Lorena Sde C; Abensur H; Elias RM; Moysés RM; Castro MC; Romão Júnior JE
Rev Assoc Med Bras (1992); 2009; 55(2):220-5. PubMed ID: 19488662
[TBL] [Abstract][Full Text] [Related]
53. Gadolinium-associated nephrogenic systemic fibrosis.
Schlaudecker JD; Bernheisel CR
Am Fam Physician; 2009 Oct; 80(7):711-4. PubMed ID: 19817341
[TBL] [Abstract][Full Text] [Related]
54. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
Boyd AS; Sanyal S; Abraham JL
J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
[TBL] [Abstract][Full Text] [Related]
55. Ten-year experience with nephrogenic systemic fibrosis: case-control analysis of risk factors.
Bahrami S; Raman SS; Sauk S; Salehmoghaddam S; Villablanca JP; Finn JP; Lu DS
J Comput Assist Tomogr; 2009; 33(6):819-23. PubMed ID: 19940643
[TBL] [Abstract][Full Text] [Related]
56. Gadolinium-based contrast agents in children.
Rozenfeld MN; Podberesky DJ
Pediatr Radiol; 2018 Aug; 48(9):1188-1196. PubMed ID: 30078039
[TBL] [Abstract][Full Text] [Related]
57. Contemporary applications and limitations of magnetic resonance imaging contrast materials.
Natalin RA; Prince MR; Grossman ME; Silvers D; Landman J
J Urol; 2010 Jan; 183(1):27-33. PubMed ID: 19913804
[TBL] [Abstract][Full Text] [Related]
58. Nephrogenic systemic fibrosis in Denmark--a nationwide investigation.
Elmholdt TR; Olesen AB; Jørgensen B; Kvist S; Skov L; Thomsen HS; Marckmann P; Pedersen M
PLoS One; 2013; 8(12):e82037. PubMed ID: 24349178
[TBL] [Abstract][Full Text] [Related]
59. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?
Weinreb JC; Abu-Alfa AK
J Magn Reson Imaging; 2009 Dec; 30(6):1236-9. PubMed ID: 19938035
[TBL] [Abstract][Full Text] [Related]
60. Gadolinium and nephrogenic systemic fibrosis: have we overreacted?
Penfield JG; Reilly RF
Semin Dial; 2011; 24(5):480-6. PubMed ID: 21913988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
